作者:E.Sathyajith Kumarasinghe、Matt A Peterson、Morris J Robins*
DOI:10.1016/s0040-4039(00)01566-5
日期:2000.11
6-lithiation/iodination to give 5-(alkyn-1-yl)-6-iodo-(1-methyluracil or uridine) intermediates (57–80%). Coupling of the 5-(alkyn-1-yl)-6-iodo intermediates gave 5,6-bis(alkyn-1-yl)pyrimidines and protected nucleosides (51–79%). Two of the 5,6-bis(ethynyl)-1,3-dimethyluracil derivatives underwent Bergman cycloaromatization at 130°C with half-lives of 2–8 h.
5-碘-1-甲基尿嘧啶或5'- O -TBDMS-5-iodo-2',3'- O-异丙基亚氨基尿嘧啶与炔烃的Sonogashira偶联产生5-(炔基-1-基)衍生物,经过6-锂化/碘化得到5-(炔-1-基)-6-碘-(1-甲基尿嘧啶或尿苷)中间体(57-80%)。5-(炔-1-基)-6-碘中间体的偶合得到5,6-双(炔-1-基)嘧啶和受保护的核苷(51-79%)。5,6-双(乙炔基)-1,3-二甲基尿嘧啶衍生物中的两个在130°C进行了Bergman环芳构化,半衰期为2-8小时。